Colombia Organ Transplant Immunosuppressant Drugs Market is expected to grow at a CAGR of 1.0% in the forecast period 2020 to 2027. The years considered for study are as mentioned below.
Colombia organ transplant immunosuppressant drugs market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased various strategic developments owing to favourable market scenario.
The major players dealing in Colombia organ transplant immunosuppressant drugs market are introducing strong range of product portfolio. This has also helped the company to maximize the sales with enhanced product portfolio.
Novartis AG is the dominating player in the organ transplant immunosuppressant drugs market. The other players in the market include Pfizer Inc., F. Hoffmann-La Roche Ltd, Astellas Pharma Inc. Bristol-Myers Squibb Company, Sanofi, Alkem Labs, Bayer AG, Abbott, Dr. Reddy’s Laboratories Ltd. among others.
Novartis AG., headquartered in Basel, Switzerland was Incorporated in 1996. The company is focusing on providing innovation in medicines for healthcare needs. The company is providing product under Innovative Medicines, Sandoz, Alcon segments. The company is continuously engaged in manufacturing and developments of organ transplant immunosuppressant drugs.
It has its global networks through direct sales representatives and distributors in Americas, Asia-Pacific, Europe, Middle East and Africa through its subsidiaries in Sandoz International GmbH (Germany), AveXis, Inc. (U.S.), Hexal AG (Germany), Novartis India Ltd. (India), Novartis Pharmaceuticals UK Limited (UK), among others.
Pfizer Inc. headquartered in New York, U.S. was Founded in 1849. The main focus of the company is to develop and distribute medicines in therapeutic areas of all diseases. The company is providing products under Internal Medicine, Vaccines, Oncology, Inflammation and Immunology, Rare Disease, Anti- Infectives categories. The company is operating Innovative Health (IH), Essential Health (EH) segments. The company is continuously engaged in manufacturing and developments of organ transplant immunosuppressant drugs.
The company has wide global presence across the globe such as North America, South America, Europe, Asia-Pacific, Middle East and Africa. In addition to it, the company also generates its revenue from the various subsidiary companies such as Agouron Pharmaceuticals, LLC (U.S.), AHP Holdings B.V. (Netherlands), Alacer Corp. (U.S.), Alpharma Pharmaceuticals LLC (U.S.), Bioren, LLC (U.S.) and G. D. Searle & Co. Limited (U.K.) among others.
F. Hoffmann-La Roche Ltd:
F. Hoffmann-La Roche Ltd has headquartered in Basel, Switzerland. The company focuses on the development, sales and manufacturing pharmaceuticals and diagnostics products. The company is providing product Pharmaceuticals, Solutions for Diagnostics, Products for Researchers Product Categories. The company is providing product under Pharmaceuticals, Diagnostics. The Company engaged in business expansion through strategic agreement of organ transplant immunosuppressant drugs products.
The company has wide global presence across the globe such as Europe, North America, Asia-Pacific, Africa, Oceania. In addition to it, the company also generates its revenue from the various subsidiary companies such as Genentech, Inc.(U.S.), Roche Diagnostics Limited (U.K), Chugai Pharmaceutical Co (Japan), Flatiron Health, Inc. (U.S.), Ventana Medical Systems (U.S.), Kapa Biosystems, Inc. (U.S.), among others